计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 1 篇同行评审文献引用。
Delgocitinib (JTE-052) is a specific JAK inhibitor with IC 50 s of 2.8, 2.6, 13 and 58 nM for JAK1 , JAK2 , JAK3 and Tyk2 , respectively
In Vitro
In the enzymatic assays, Delgocitinib potently inhibits all of the JAK subtypes with IC 50 values of 2.8±0.6, 2.6±0.2, 13±0 and 58±9 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. Lineweaver-Burk plots show that the inhibition mode of Delgocitinib toward all JAKs is competitive with ATP with K i values of 2.1±0.3, 1.7±0.0, 5.5±0.3 and 14±1 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. In these cell-based cytokine signaling assays, Delgocitinib inhibits the phosphorylation of Stat proteins induced by IL-2, IL-6, IL-23, GM-CSF, and IFN-α with IC 50 values of 40±9, 33±14, 84±11, 304±22 and 18±3 nM, respectively. Delgocitinib also inhibits IL-2-induced proliferation of T cells in a concentration-dependent manner (IC 50 =8.9±3.6 nM), and its potency is similar to that of CP-690550 (IC 50 =16 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Delgocitinib decreases the IFN-γ production, but the potency of the 1-h prior administration is higher than that of the 6-h prior administration (ED 50 =0.24 versus 1.3 mg/kg). In the administration from day 1, Delgocitinib prevents the development of hind paw swelling and histological changes of inflammatory cell infiltration and synovial cell hyperplasia. Delgocitinib inhibits radiographic and histological changes of bone destruction and cartilage destruction. In the administration from day 15, Delgocitinib decreases the paw swelling in a dose-dependent manner. In addition, Delgocitinib ameliorates the inflammatory cell infiltration, synovial cell hyperplasia, and cartilage/bone destructions in the histological and radiographic examinations at the end of the study . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:JAK2 2.6 nM (IC 50 ) JAK1 2.8 nM (IC 50 ) JAK3 13 nM (IC 50 ) Tyk2 58 nM (IC 50 )
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 吡咯并嘧啶 |
| 亚类(Subclass) | 吡咯并[2,3-d]嘧啶 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 吡咯并[2,3-d]嘧啶 |
| 其他上位类(Alternative Parents) | 二烷基芳胺 氨基嘧啶及其衍生物 咪唑内酰胺类 叔羧酸酰胺 吡咯烷 吡咯类 杂芳族化合物 氮杂环丁烷 氨基酸及其衍生物 腈类 氮杂环化合物 有机氧化物 碳氢化合物衍生物 羰基化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 氨基酸 - 氨基酸或其衍生物 - 氨基吡啶 - 芳香族杂多环化合物 - 氮杂环 - 氮杂环丁烷 - 碳腈 - 羰基 - 羧酰胺基 - 羧酸衍生物 - 氰化物 - 二烷基芳基胺 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 氰基化合物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 嘧啶 - 吡咯 - 吡咯烷 - 吡咯并[2,3-d]嘧啶 - 三芳基胺 - 叔羧酸酰胺 |
| 描述(Description) | 该化合物属于吡咯并[2,3-d]嘧啶类有机化合物。这类芳香杂多环化合物含有吡咯并[2,3-d]嘧啶环系,即吡咯嘧啶异构体,其三个环氮原子分别位于1、5和7位。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|